Closed Opportunities

BAA for DARPA's Biological Technologies Office

LifeArc has made available an initial £10M for the identification of therapeutics that can be rapidly deployed to treat COVID-19. The aim is to run trials in patients during the current epidemic. It is anticipated that applications will be for funding to repurpose one or more drugs that are generic, already licensed, or are in late stage development for another indication.

Offerors may submit a proposal in response to one, or more, of the Research Areas contained herein. Offers submitted in response to this BAA must present separate detailed technical and business proposals designed to meet the Technical Objectives described for each Research Area proposed. The Statement of Work (SOW), including the specific technical requirements and performance specifications, shall be developed and proposed by the Offeror, not the Government.

This is a forecast for an emergency supplemental funding opportunity announcement in response to the current outbreak of Coronavirus disease 2019 (COVID-19).Please note the following important details:1) The purpose of this notice of funding opportunity (NOFO) is to announce the availability of supplemental funding for the organizations that were previously awarded funding under Funding Strategy 1 of CDC-RFA-OT18-1802: "Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health" in FY18. 2) Organizations meeting this criteria are eligible to apply for new CIO Project Plans specifically intended to address the current outbreak of COVID-19, and may apply according to the Target Population Category (A,B, or C) and Target Population for which they received initial funding in FY18.3) This emergency supplemental will utilize FY 2020 funding, but will fund projects in Year 2 (not Year 3) of CDC-RFA-OT18-1802.4)

The American Heart Association (AHA) invites cardiovascular-focused applications that will contribute to understanding the cardiovascular and cerebrovascular pathogenesis, diagnosis, prevention, clinical manifestations, clinical management (including critical care management) and social behaviors which can lead to dissemination, containment, and complications of COVID-19. Because of the urgency of this issue, innovative, highly impactful short-term proposals (9-12 months), which can show progress within the period of this award, are sought.

Grant amounts will be up to $100,000, including up to 10 percent institutional indirect costs. The AHA anticipates funding at least 10 awards and a nationwide Coordinating Center.

The listed topics of interest are:
• Topic #1: Surveillance, natural history and household transmission of SARS CoV-2 DVD/RVB
• Topic #2: Diagnostics development and novel technology development and evaluation to improve diagnostic testing capabilities for COVID-19 detection DVD/RVB
• Topic #3: Immune response and transmission dynamics for SARS CoV-2 DVD/RVB
• Topic #4: Host infection dynamics for SARS CoV-2 DVD/RVB
• Topic #5: Prospective Cohorts to Assess COVID-19 and Other Respiratory Diseases